H.C. Wainwright maintains Buy rating on Kymera Therapeutics stock

On Tuesday, H.C. Wainwright analysts reiterated a Buy rating for Kymera Therapeutics stock (NASDAQ: KYMR) and maintained a price target of $54.00. According to InvestingPro data, the stock has seen a remarkable 53% surge in the past week, with analyst targets ranging from $51 to $97. This decision follows the release of the first-in-human trial data for KT-621, a STAT6 degrader, which analysts believe significantly reduces risk for the upcoming Phase 1b trial and two potential Phase 2 trials. The company maintains a strong financial position with a current ratio of 8.49, holding more cash than debt on its balance sheet.

The analysts noted that the recent data supports the likelihood of selecting doses between 50-100 mg for proof-of-concept trials. They highlighted that in the Phase 1b trial, the M4 trial of dupilumab, a 4-week monotherapy, showed a progressive reduction in TARC levels, with median decreases of 20-25% within 5 days, 40% by 10 days, 60% by 15 days, and 70% by 28 days.

In contrast, IgE levels decreased more gradually, attributed to IgE’s longer half-life. The analysts observed significant dose-dependent changes in RNA expression profiles in patients after four weeks of dupilumab treatment at doses of 150 mg or 300 mg, indicating broad effects on gene regulation.

The analysts emphasized the importance of these findings, noting that they support the ongoing development and future trials of Kymera’s KT-621. They reiterated their confidence in the company’s strategy and potential for successful outcomes in upcoming trials. With a market cap of $2.8 billion and strong momentum, investors can access detailed analysis and 12 additional ProTips through InvestingPro’s comprehensive research report.

In other recent news, Kymera Therapeutics has seen a series of positive developments regarding its oral STAT6 degrader, KT-621. The release of first-in-human data for KT-621 has met key benchmarks for target engagement and safety, prompting B. Riley to upgrade Kymera’s stock rating from Neutral to Buy and raise the price target to $60. Similarly, Citi analysts increased their price target for Kymera to $60, maintaining a Buy rating, following promising Phase 1 data that demonstrated near-complete STAT6 degradation and an excellent safety profile. Morgan Stanley (NYSE:MS) also upgraded the stock from Equalweight to Overweight, raising the price target to $79, citing optimism about Kymera’s prospects and the promising development of KT-621, especially for dermatology applications. Truist Securities reaffirmed their Buy rating, maintaining a price target of $53, after positive clinical results from the Phase 1 study of KT-621. Wells Fargo (NYSE:WFC) reiterated its Overweight rating, maintaining a price target of $57, expressing confidence in the stock’s potential growth as it approaches the Phase 1b data release. These analyst actions reflect a growing confidence in Kymera’s trajectory and its potential for growth in the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.